KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

IV Fosphenytoin for Acute Trigeminal Neuralgia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Shusaku Noro, Toru Hatayama, Yoshiyasu Iwai, Hiroki Toda, Junta Moroi, Yoichiro Abe, Bunsho Asayama, Hirohiko Nakamura

Neurology 106(11) e218037

PMID42096672
PMCIDPMC13165287
DOI10.1212/WNL.0000000000218037
发表日期2026-05-07
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。
摘要

摘要

BACKGROUND AND OBJECTIVES: Trigeminal neuralgia (TN) is a debilitating condition characterized by sudden, severe facial pain. IV medications for acute TN exacerbations have not been investigated in randomized controlled trials (RCTs). Oral medications are often insufficient for acute attacks, and surgery is not immediately available. We conducted an RCT to evaluate IV fosphenytoin therapy (IFT) as a rapid-acting rescue treatment for acute TN exacerbations. We hypothesized that, compared with placebo, IFT would reduce acute TN pain. METHODS: This multicenter, double-blind, placebo-controlled phase 3 trial was conducted at 6 institutions (April 2023-April 2024). Patients with classical or idiopathic TN who were experiencing TN exacerbation (numerical rating scale [NRS] score ≥5) were recruited from emergency and outpatient settings, and all study drugs were administered during hospital admission. Participants were randomized 1:1 to IFT (initial dose: 18 mg/kg, maintenance: 7.5 mg/kg for 4 days) or placebo. The primary end point was the change in NRS pain scores from baseline to 120 minutes after the initial dose. Secondary end points included attack frequency, the proportion achieving ≥50% NRS score improvement, and adverse events. Data were collected by blinded personnel and analyzed using repeated-measures mixed-effects models. RESULTS: Of 31 participants screened, 22 were randomized; 1 placebo-assigned participant did not meet the NRS ≥5 criterion and was excluded, leaving 21 for analysis (IFT: 11; placebo: 10). Participants had a mean age of 65.2 years (range 42-83; 8 men, 13 women). Compared with placebo, IFT significantly reduced pain (NRS change: -6.1 vs -2.4; between-group difference -3.8; 95% CI -6.4 to -1.1; p = 0.008), decreased attack frequency within 24 hours (2.5 ± 5.3 vs 16.1 ± 19.6, difference -13.6; 95% CI -26.4 to -0.7), and increased the proportion achieving ≥50% NRS improvement (90.9% vs 40.0%, difference 50.9%; 95% CI 5.6%-81.6%). Adverse events (somnolence, hypotension, and nausea) were mild and transient. DISCUSSION: IFT provided rapid and well-tolerated pain relief in acute TN exacerbations. Although findings are preliminary because of the small sample size, IFT may be a viable short-term treatment option, meriting further investigation. TRIAL REGISTRATION INFORMATION: Japan Registry of Clinical Trials, jRCT2011220043. Registered March 3, 2023. First enrollment April 25, 2023. jrct.mhlw.go.jp/en-latest-detail/jRCT2011220043. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that in patients with acute TN exacerbations, IV fosphenytoin is superior to placebo in reducing pain intensity at 120 minutes.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. CONSORT Randomization Flow Diagram Thirty-one participants were screened for eligibility, and 22 underwent randomization. Nine participants who provided informed consent were not randomized because they did not meet the inclusion criteria of NRS score ≥5 during the observation period. After excluding 1 patient with an NRS score < 5 immediately before drug administration, 21 participants were analyzed. Some participants did not receive subsequent maintenance doses based on the investigators' judgment that the initial dose resulted in either complete pain relief or insufficient response. CONSORT = Consolidated Standards of Reporting Trials; NRS = numerical rating scale.
非 KM Figure
Figure 2Figure 2. Changes in NRS Scores After IFT (A) The average NRS scores with standard deviations for all participants (IFT, n = 11; placebo, n = 10) who received the initial drug dose. (B) Changes in NRS scores from baseline to 120 minutes after drug administration with 95% CIs for all participants (IFT, n = 11; placebo, n = 10) who received the initial drug dose. IFT = IV fosphenytoin therapy; NRS = numerical rating scale.
非 KM Figure
Figure 3Figure 3. Frequency and Incidence of Trigeminal Neuralgia Attacks by Treatment Group (A) The percentage of participants experiencing trigeminal neuralgia attacks. The assessment time points were 15 minutes, 30 minutes, 45 minutes, 60 minutes, 75 minutes, 90 minutes, 105 minutes, 120 minutes, 4 hours, 6 hours, and 8 hours after starting administration; before bedtime; and immediately before starting maintenance administration. The following conditions were applied to calculate cumulative attacks across all time points for each patient: 8 time points (15–120 minutes): “Yes” = 1 time. 5 time points (4 hours to immediately before starting maintenance administration): “0 times” = 0 times, “1–5 times” = 1 time, “6–10 times” = 6 times, “>11 times” = 11 times. In addition, if attacks continued across multiple assessment time points, they were counted at each time point. The p value corresponds to the treatment-by-visit interaction from a post hoc generalized linear mixed-effects model with time treated as a categorical variable ( p = 0.205). (B) Number of trigeminal neuralgia attacks. Average number of trigeminal neuralgia attacks with standard error. The p value was calculated using the Student t test, as specified in the statistical analysis plan. Corresponding 95% CIs were also derived. IFT = IV fosphenytoin therapy.
非 KM Figure